IREB2 and colorectal carcinoma: Recent high-throughput screening of an 8-million compound library identified IRP2 inhibitors, indicating that genetic deletion or pharmacological inhibition of IRP2 inhibits the growth of colorectal cancer (CRC) cells, underscoring the therapeutic potential of targeting IRP2 in oncology [11].